# 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

> **NCT00905632** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 75 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 207127 middle dose +SOC
- **DRUG:** BI 207127 high dose+SOC
- **DRUG:** Placebo + SOC
- **DRUG:** BI 207127 low dose + SOC

## Key facts

- **NCT ID:** NCT00905632
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00905632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00905632, "4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00905632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*